Azacitidine-induced myopericarditis in acute myeloid leukemia.
Mahmoud IsmaylAsmini KcAbhishek ThandraNattapong SricharoenAmy ArouniPublished in: Proceedings (Baylor University. Medical Center) (2022)
Hypomethylating agents are commonly used in the treatment of myelodysplastic syndromes and are known to cause bone marrow suppression; however, cardiac complications are rare. We describe a patient who was diagnosed with acute myeloid leukemia and developed myopericarditis after receiving chemotherapy with azacitidine. Our case highlights the importance of a thorough history, including medication review, in patients with suspected myopericarditis. It also raises awareness about the potential cardiac side effects of azacitidine.
Keyphrases
- acute myeloid leukemia
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- left ventricular
- mesenchymal stem cells
- healthcare
- high glucose
- case report
- risk factors
- diabetic rats
- locally advanced
- squamous cell carcinoma
- risk assessment
- emergency department
- adverse drug
- combination therapy
- rectal cancer
- climate change
- replacement therapy